|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Cirrhotics of the study population A with low Δ-MELDNa | Cirrhotics of the study population A with high Δ-MELDNa | P value |  | Cirrhotics of the study population B with low Δ-MELDNa | Cirrhotics of the study population B with high Δ-MELDNa | P value |
| Age, median (IQR) | 51.0 (45.0-59.0) | 54.0 (49.0-60.8) | 0.239 | 56.5 (52.3-60.3) | 59.1 (52.1-63.7) |  |
| Male sex, n (%) | 10 (76.9) | 12 (85.7) | 0.648 | 12 (80.0) | 15 (93.8) |  |
| BMI (Kg/m2), median (IQR) | 24.1 (22.6-28.4) | 24.3 (22.9-26.7) | 0.943 | 25.9 (24.0-29.7) | 25.7 (24.5-28.7) |  |
| Cirrhosis aetiology, n (%):  MAFLD  Alcohol  Viral | 7 (53.8)  5 (38.5)  9 (69.2) | 9 (64.3)  5 (35.7)  10 (71.4) | 0.704  1  1 | 9 (60.0)  10 (66.7)  4 (26.7) | 8 (50.0)  6 (37.5)  8 (50.0) | 0.576  0.156  0.273 |
| HCC, n (%) | 8 (61.5) | 6 (42.9) | 0.449 | 9 (60.0) | 8 (50.0) | 0.576 |
| Diuretic treatment, n (%):  No  K sparing diuretics only  Loop diuretics plus K sparing diuretics | 4 (30.8)  0 (0)  9 (69.2) | 4 (28.6)  3 (21.4)  7 (50.0) | 0.331 | 5 (33.3)  1 (6.7)  9 60.0) | 6 (37.5)  3 (18.8)  7 (43.8) | 0.621 |
| MELDNa at transplant, median (IQR) | 16.0 (12.2-23.0) | 19.0 (14.8-21.8) | 0.402 | 14.0 (10.0-23.0) | 22.0 (14.0-28.8) | **<0.001** |
| MELDNa at listing, median (IQR) | 15.9 (12.2-25.7) | 14.6 (11.4-17.8) | 0.280 | 15.9 (12.8-22.5) | 17.6 (9.8-28.8) | 0.830 |
| Δ-MELDNa, median (IQR) | 0.0 (-1.31 – 0.0) | 1.09 (0.24-3.51) | 0.059 | -0.31 (-1.84-0.08) | 3.23 (1.34-10.83) | **<0.001** |
| Serum AST (IU/L), median (IQR) | 41.0 (35.5-70.0) | 88.0 (58.5-115.3) | **0.009** | 43.0 (28.0-59.0) | 93.0 (61.0-139.5) | **0.001** |
| Serum ALT (IU/L), median, (IQR) | 32.0 (24.5-59.0) | 51.0 (43.5-95.3) | 0.089 | 29.0 (20.0-48.0) | 59.5 (36.3-84.8) | **0.002** |
| Serum Mg, mg/dL, median (IQR) | NAV | NAV | - | 1.90 (1.70-2.11) | 1.75 (1.63-1.94) | 0.188 |
| Tissue Mg, (µg/g), median, (IQR) \* | 118.7 (113.3-140.6) | 114.7 (102.8-125.8) | 0.280 | NAV | NAV |  |
| Percentage of weak positive hepatocytes to TRPM7 stain, median (IQR) | NAV | NAV | - | 42.8 (24.6-56.2) | 50.2 (40.7-56.3) | 0.299 |
| Percentage of intense positive hepatocytes to TRPM7 stain, median, (IQR) | NAV | NAV | - | 0.6 (0.0-4.0) | 7.0 (1.8-17.3) | **0.001** |
| Percentage of total positive hepatocytes to TRPM7 stain, median (IQR) | NAV | NAV | - | 46.8 (24.8-56.2) | 55.4 (50.9-73.6) | 0.045 |
| \* Measured by atomic absorption. All data refer to the time of liver transplant, unless otherwise specified  Abbreviation: AST aspartate amino transferase; ALT alanine amino transferase; BMI: body mass index; HCC, hepatocellular carcinoma; IQR, interquartile range; K, potassium; MAFLD, metabolic associated fatty liver disease; MELD, model of end stage liver disease; MELDNa, MELD with added a serum sodium concentration parameter; Mg, magnesium; NAV, not available; Δ, delta. | | | | | | | | |

**Supplementary table 2.** Demographic and clinical characteristics of the cirrhotic patients of the study populations A and B, subgrouped according to the respective median value of Δ-MELDNa during the waitlist time